The Wall Street Journal reported on Tuesday that Eli Lilly (LLY.US) is in advanced negotiations to acquire Ventyx Biosciences (VTYX.US) for over $1 billion. Ventyx's stock price surged more than 50% in after-hours trading.
The potential acquisition of Ventyx would add drugs for the treatment of inflammatory bowel disease and drugs for diseases such as Parkinson's to Eli Lilly's product pipeline. Additionally, one of Ventyx's experimental drugs is currently in mid-stage development for the treatment of obesity-related cardiovascular diseases

VTYX

Eli Lilly is in talks to acquire Ventyx Biosciences for over $1 billion, according to The Wall Street Journal. This deal could expand Eli Lilly's product line to include drugs for the treatment of inflammatory bowel disease and Parkinson's disease. One of Ventyx's experimental drugs is also in mid-stage development aimed at treating obesity-related cardiovascular diseases. Ventyx's stock price rose more than 50% in after-hours trading

According to reports, Eli Lilly plans to acquire Ventyx Biosciences for over $1 billion